NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

AARD

Aardvark Therapeutics Inc

Jul 03 • 03:12PM ET

13.92

Dollar change +0.40
Percentage change 2.96	%

Healthcare • Biotechnology • USA • NASD

Held by: VXF IWM VTI IWO IWN IWC VTWO RSSL UWM URTY

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.16	Insider Own	42.89%	Shs Outstand	21.69M	Perf Week	0.43%
Market Cap	302.01M	Forward P/E	-	EPS next Y	-2.67	Insider Trans	18.67%	Shs Float	12.39M	Perf Month	19.38%
Enterprise Value	151.48M	PEG	-	EPS next Q	-0.60	Inst Own	21.98%	Short Float	2.91%	Perf Quarter	48.88%
Income	-27.72M	P/S	-	EPS this Y	51.38%	Inst Trans	10.87%	Short Ratio	4.68	Perf Half Y	-
Sales	0.00M	P/B	2.00	EPS next Y	-6.71%	ROA	-46.77%	Short Interest	0.36M	Perf YTD	-2.73%
Book/sh	6.95	P/C	2.00	EPS next 5Y	16.89%	ROE	-110.36%	52W High	19.58 -28.91%	Perf Year	-
Cash/sh	6.97	P/FCF	-	EPS past 3/5Y	-22.31% -	ROIC	-18.35%	52W Low	4.88 185.25%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.44% 11.13%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.31	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	25.86	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	59.96	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	25.86	EPS Q/Q	49.54%	SMA20	10.53%	Beta	-	Target Price	33.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	23.56%	Rel Volume	0.14	Prev Close	13.52
Employees	22	LT Debt/Eq	0.00	Earnings	May 14 AMC	SMA200	29.93%	Avg Volume	76.88K	Price	13.92
IPO	Feb 13, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	-5.45% -	Trades		Volume	10,562	Change	2.96%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-30-25	Initiated	H.C. Wainwright	Buy	$40
Mar-10-25	Initiated	RBC Capital Mkts	Outperform	$21
Mar-10-25	Initiated	Morgan Stanley	Overweight	$29
Mar-10-25	Initiated	Cantor Fitzgerald	Overweight	$50
Mar-10-25	Initiated	BofA Securities	Buy	$22

Jul-01-25 05:31PM	Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress (Benzinga)
Jun-24-25 08:00AM	Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference (GlobeNewswire) +18.23%
Jun-03-25 09:55AM	Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet (Zacks)
May-19-25 04:10PM	Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions (GlobeNewswire) +5.46% +5.47%
May-14-25 04:10PM	Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire) -13.81%
04:05PM	Loading…
May-07-25 04:05PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in May (GlobeNewswire)
Mar-31-25 04:10PM	Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +10.39%
Mar-27-25 04:18PM	Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower (Investor's Business Daily) -5.52% -13.03%
Mar-21-25 09:20AM	Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (SeekingAlpha) +7.95%
Mar-14-25 11:25AM	Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-03-25 02:55PM	Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-12-25 10:38PM	Aardvark Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Decheng Capital Global Life Sc	10% Owner	Feb 14 '25	Buy	16.00	1,250,000	20,000,000	2,958,887	Feb 19 05:44 PM
Lee Tien-Li	Chief Executive Officer	Feb 14 '25	Buy	16.00	16,542	264,672	1,496,175	Feb 19 04:35 PM
Sun Nelson	Chief Financial Officer	Feb 14 '25	Buy	16.00	10,000	160,000	99,484	Feb 19 04:30 PM
Cormorant Asset Management, LP	Former 10% Owner	Feb 14 '25	Buy	16.00	187,500	3,000,000	987,689	Feb 19 04:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AARD

Aardvark Therapeutics Inc

Upgrade your FINVIZ experience